Dose-Response Modeling for Inhalational Anthrax in Rabbits Following Single or Multiple Exposures

Risk Analysis : an Official Publication of the Society for Risk Analysis
Bradford W GuttingBrandolyn Thran

Abstract

There is a need to advance our ability to characterize the risk of inhalational anthrax following a low-dose exposure. The exposure scenario most often considered is a single exposure that occurs during an attack. However, long-term daily low-dose exposures also represent a realistic exposure scenario, such as what may be encountered by people occupying areas for longer periods. Given this, the objective of the current work was to model two rabbit inhalational anthrax dose-response data sets. One data set was from single exposures to aerosolized Bacillus anthracis Ames spores. The second data set exposed rabbits repeatedly to aerosols of B. anthracis Ames spores. For the multiple exposure data the cumulative dose (i.e., the sum of the individual daily doses) was used for the model. Lethality was the response for both. Modeling was performed using Benchmark Dose Software evaluating six models: logprobit, loglogistic, Weibull, exponential, gamma, and dichotomous-Hill. All models produced acceptable fits to either data set. The exponential model was identified as the best fitting model for both data sets. Statistical tests suggested there was no significant difference between the single exposure exponential model results and the m...Continue Reading

References

Sep 9, 1999·The New England Journal of Medicine·T C DixonP C Hanna
Sep 7, 2001·Annual Review of Microbiology·M Mock, A Fouet
May 23, 2002·Risk Analysis : an Official Publication of the Society for Risk Analysis·Charles N Haas
Oct 25, 2002·Emerging Infectious Diseases·Daniel B JerniganUNKNOWN National Anthrax Epidemiologic Investigation Team
Oct 25, 2002·Emerging Infectious Diseases·Puneet K DewanUNKNOWN Washington, D.C., Anthrax Response Team
Jun 5, 2003·Emerging Infectious Diseases·Timothy H HoltzMarcelle Layton
Nov 18, 2006·Journal of Thoracic Imaging·Aletta Ann FrazierJeffrey R Galvin
Jun 17, 2008·Risk Analysis : an Official Publication of the Society for Risk Analysis·Timothy A BartrandCharles N Haas
Jun 28, 2008·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Margaret E ColemanStacey Massulik
Apr 17, 2009·Environmental Science & Technology·Phillip N PriceJennifer A McWilliams
Jul 16, 2010·Risk Analysis : an Official Publication of the Society for Risk Analysis·Tao HongNicholas F Dudley Ward
Sep 3, 2011·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Ellen Raber
Oct 28, 2011·Environmental Science & Technology·Igor LinkovJeffrey Keisler
Apr 4, 2012·Risk Analysis : an Official Publication of the Society for Risk Analysis·Sarah C Taft, Stephanie A Hines
Aug 25, 2012·Frontiers in Cellular and Infection Microbiology·Roy E BarnewallSarah C Taft
Apr 10, 2013·Journal of Theoretical Biology·Bradford W GuttingAndrey Rukhin
Dec 30, 2014·Risk Analysis : an Official Publication of the Society for Risk Analysis·Bradford W GuttingBrandolyn Thran
May 7, 2015·Risk Analysis : an Official Publication of the Society for Risk Analysis·Michael A HamiltonPatrick L Gurian
May 12, 2015·Environmental Science & Technology·Tao Hong, Patrick L Gurian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

Risk Analysis : an Official Publication of the Society for Risk Analysis
Charles N Haas
Risk Analysis : an Official Publication of the Society for Risk Analysis
Sarah C Taft, Stephanie A Hines
Nihon saikingaku zasshi. Japanese journal of bacteriology
Eiko Yabuuchi
© 2022 Meta ULC. All rights reserved